MRPL19: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Target Name: MRPL19

NCBI ID: G9801

MRPL19

MRPL19: A Potential Drug Target and Biomarker for Mitochondrial Disorders

Abstract:

Mitochondrial dysfunction is a neurodegenerative disorder that affects the power production by the mitochondria, leading to a range of symptoms, including cognitive impairments, fatigue, and muscle weakness. The 39S ribosomal protein L19 (MRPL19) is a protein that is expressed in the mitochondria and is involved in the assembly and function of the 39S ribosome, which is responsible for producing the majority of the proteins in the cell. The aim of this article is to discuss the potential drug target and biomarker properties of MRPL19, with a focus on its involvement in mitochondrial dysfunction and its potential as a therapeutic target.

Introduction:

Mitochondrial dysfunction is a complex neurodegenerative disorder that is characterized by a range of symptoms, including cognitive impairments, fatigue, muscle weakness, and neuroinflammation. The mitochondria are responsible for producing the majority of the energy in the cell and are also responsible for maintaining the structural integrity of the cells. When the mitochondria are damaged or dysfunctional, they are unable to produce enough energy, leading to a range of symptoms.

MRPL19: A Protein expression and function

MRPL19 is a protein expressed in eukaryotic cells and mainly exists in the cytoplasm. This protein is encoded by a gene and forms the 39S ribosome together with 39S ribosomal protein L2 (rpL2). 39S r

Protein Name: Mitochondrial Ribosomal Protein L19

The "MRPL19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets